Until such evidence is available for retatrutide, therapies with established cardiovascular and renal benefitssuch as semaglutide, supported by SUSTAIN-6 [5] and FLOW [57] trials in people with T2D, and the SELECT trial [58] in people with obesity - should be prioritised in populations with existing cardio-renal disease
Another randomized trial showed a 31.6% reduction in wrinkle volume compared to controls
When taken as directed by a healthcare professional, it helps support kidney wellness, reduce oxidative stress, and contribute to better overall renal health
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome
What if you wanted a different concentration
New biotechnological methods to reduce oxidative stress in the cardiovascular system: Focusing on the Bach1/heme oxygenase-1 pathway